The Role of Impella in Cardiogenic Shock in the Post-DanGer Shock Era

The microaxial flow pump (mAFP) is a mechanical circulatory support device designed to directly unload the left ventricle, restore cardiac output, and improve systemic perfusion in the setting of cardiogenic shock (CS). CS is a devastating complication of acute myocardial infarction (AMI) and advanced heart failure, characterized by systemic hypoperfusion and myocardial dysfunction, carrying an in-hospital mortality of 30–50%. However, there has been controversy about whether these theoretical physiological mechanisms behind mAFP translate into actual survival or recovery in this patient population that has historically been difficult to study in prospective trials. The lack of consensus has resulted in differing national guidelines, resource allocation, and clinical decision-making in time-sensitive clinical scenarios. Earlier studies were limited to retrospective analyses and a single small, underpowered randomized trial, none of which showed a mortality benefit. In 2024, the DanGer Shock trial emerged as the first multi-center trial to demonstrate mortality benefit in patients with STEMI complicated by CS treated with Impella CP, albeit at the cost of increased risk of major bleeding, hemolysis, and vascular complications, an effect sustained in the 10 year outcomes published in 2025. In this review, we examine reasons for the differing results of preceding studies and compare how multinational guidelines have reacted to this new evidence. Finally, we provide practical considerations regarding the use, complications, and troubleshooting of this technology, and identify gaps in evidence regarding patient selection and timing of placement.